选择性髓性白血病-1抑制剂的化学剖析:它们是如何被发现和演变的
Luyao Wang1, Yuxiang Chen1, Maoqian Zhang1
1School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
European journal of medicinal chemistry
|December 21, 2024
概括
骨髓细胞白血病-1 (MCL-1) 对于癌细胞生存和耐药性至关重要. 本综述详细介绍了MCL-1抑制剂,它们的结构演变,以及在癌症治疗中克服治疗耐药性的潜力.
科学领域:
- 分子生物学分子生物学
- 癌症生物学 癌症生物学
- 药物发现 药物发现 药物发现
背景情况:
- 骨髓细胞白血病-1 (MCL-1) 是BCL-2家族中的一个关键的抗亡蛋白,对细胞存活至关重要.
- 过度表达MCL-1经常与各种癌症的治疗耐药性有关.
- 了解MCL-1在细胞灭亡和细胞平衡中的作用对于癌症治疗至关重要.
研究的目的:
- 为MCL-1的结构和功能提供全面的概述.
- 分析选择性MCL-1抑制剂的结构发展和优化.
- 探索针对癌症中的MCL-1的新策略和组合.
主要方法:
- 对BCL-2介导的亡途径的审查.
- 对各种MCL-1抑制剂 (小分子,共价,金属基,PROTACs) 的详细结构分析.
- 对选择性,功效和药理动力学方面的抑制剂优化进行检查.
主要成果:
- MCL-1的独特结构决定了它与亲亡蛋白的相互作用.
- 在设计具有改进性质的选择性MCL-1抑制剂方面取得了重大进展.
- 证明了MCL-1抑制剂与其他抗癌剂的协同作用潜力.
结论:
- MCL-1 抑制剂是克服癌症药物耐药性的有希望的治疗策略.
- 结构性修改增强了抑制剂的有效性和药物动力学特征.
- 未来的研究应该专注于创新的向策略和MCL-1调节的组合疗法.
更多相关视频
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
13.9K
10:18From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
13.7K
相关概念视频
Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
